Personalis (PSNL) Q4 2024 earnings summary

Executive summary

• Achieved full year 2024 revenue of $84.6 million, up 15% year-over-year, with Q4 revenue at $16.8 million, down 15% from Q4 2023, driven by 60% biopharma growth and offset by declines in enterprise and VA MVP volumes.

• Delivered 1,441 molecular tests in Q4 2024, a 52% sequential increase, and 3,285 tests for the year versus 177 in 2023.

• Net loss for 2024 was $81.3 million, improved from $108.3 million in 2023; Q4 net loss was $16.4 million, improved from $26.6 million in Q4 2023.

• Ended 2024 with $185 million in cash, including a $50 million strategic investment from Merck, supporting clinical volume ramp and cash flow break-even goals.

• Expanded partnerships with Moderna and Tempus, and maintained high physician retention and positive feedback, with nearly 300 doctors using NeXT Personal and reorder rates in the high 90% range.

Financial highlights

• Revenue from pharma tests and services, enterprise sales, and clinical diagnostics grew 20% to $77.2 million in 2024, while population sequencing for VA MVP declined 21% to $7.4 million.

• Full year 2024 gross margin was 31.7%–32%, up from 24.8% in 2023, driven by favorable customer mix and cost reductions.

• Q4 gross margin was 27.1%, with unreimbursed test costs impacting margin by 8 percentage points; excluding these, margin would be ~35%.

• Operating expenses for 2024 were $95.1 million, down from $128.1 million in 2023, reflecting headcount reductions and absence of prior year one-time charges.

• Cash usage from operations and capital equipment was $46.8 million in 2024, down from $67.2 million in 2023.

Outlook and guidance

• 2025 revenue guidance is $80–$90 million, with Q1 2025 revenue expected at $17–$18 million.

• Clinical revenue expected to be $3–$10 million, mostly in H2 pending reimbursement.

• Gross margin for 2025 guided at 21%–23%, reflecting investment in clinical test volume ahead of reimbursement.

• Net loss for 2025 expected to be ~$85 million, including $20 million in unreimbursed test costs.

• Cash usage projected at $75–$80 million in 2025, mainly for clinical volume and commercial ramp.